The Hello Bar is a simple web toolbar that engages users and communicates a call to action.

Pfizer Receives European Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal Disease

Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved the Company’s pneumococcal conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older. “Prevenar 13, the first and only pneumococcal conjugate vaccine [...]

Pfizer Establishes Precision Medicine Research Collaboration With Medco

NEW YORK – Pfizer Inc. (NYSE: PFE) announced today that it has established a research collaboration with Medco Health Solutions, Inc. (NYSE: MHS) and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes. “We have long recognized that [...]

The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate Patients About The Flood Of Counterfeit Medicines Online

counterfeit_drugs

NEW YORK – Pfizer Inc. (NYSE: PFE) and the National Association of Boards of Pharmacy® (NABP) are launching a new effort to draw attention to the risks associated with counterfeit prescription medicines and help patients learn how to safely buy medicines online. Prescription medicines are among the most counterfeited consumer goods. Worldwide sales of counterfeit [...]

Pfizer Extends Tender Offer To Acquire Icagen, Inc.

NEW YORK & RESEARCH TRIANGLE PARK, N.C. – Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller [...]

Pfizer Wins Viagra Patent Trial

NEW YORK – Pfizer Inc. announced today that it has prevailed in its patent infringement action against Teva Pharmaceuticals USA, Inc. in the United States District Court for the Eastern District of Virginia. “We are pleased that the court recognized the validity and enforceability of our Viagra patent for the treatment of erectile dysfunction,” said [...]

Pfizer Completes Sale Of Capsugel Business To KKR

NEW YORK – Pfizer Inc. (NYSE: PFE) announced today that it has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, “KKR”), following the receipt of required regulatory clearances, including in the U.S. and the European Union. Under the terms of the previously [...]

Pfizer To Acquire Icagen

NEW YORK, N.Y., and RESEARCH TRIANGLE PARK, N.C. – Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) today announced that they have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen’s fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share. The [...]

Pfizer Affirms CHANTIX/CHAMPIX as Important Treatment Option for Smokers Wanting to Quit

NEW YORK – Pfizer said today that the reliable science on varenicline (CHANTIX/CHAMPIX), involving more than 14 clinical trials with more than 7,000 smokers, and the medicine’s approval by regulatory authorities around the world, demonstrate the importance of the medicine as an effective and appropriate treatment option for adult smokers wanting to quit. Pfizer stands [...]

Adding Inspra® (eplerenone) To Standard Therapy Reduces The Incidence Of New Onset Atrial Fibrillation/Flutter (AF/F) In Patients With Systolic Heart Failure, Sub-Analysis Shows

inspra

GOTHENBURG, Sweden – Pfizer Inc. (NYSE: PFE) today announced results from a pre-specified sub-analysis1 of the EMPHASIS-HF trial2 which showed that Inspra® (eplerenone), added to standard recommended therapy, statistically significantly reduced the incidence of new onset atrial fibrillation or flutter (AF/F) in patients with systolic heart failure and mild symptoms, compared with placebo plus standard [...]

Greenstone Announces Voluntary Nationwide Recall of Citalopram and Finasteride Due to Possible Mislabeling

PEAPACK, N.J. - Greenstone LLC announced today that it is voluntarily conducting a recall, to the patient level, of medicines with lot number FI0510058-A on the label. This includes Citalopram 10mg Tablets (100-count bottle) and Finasteride 5mg Tablets (90-count bottle), both distributed in the U.S. market. The recall is due to the possibility that incorrect labels [...]

HTML Codes

© Rx Times 2006 - 2012. All rights reserved. All products denoted with ™ and ® are trademarks or registered trademarks of Rx Times, LLC and/or its affiliates.